PM226 

PM226 is a selective cannabinoid CB2R agonist (K_i (CB2R)=13 nM; EC₅₀ (CB2R)=39 nM; K_i (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo^[1].

PM226 binds selectively to CB2 receptor with an affinity in the nanomolar range (K_i=12.8±2.4 nM). PM226 has negligible affinity for the CB1 receptor (K_i >40000 nM) and no activity at the GPR55. PM226 was also evaluated in GTPγS binding assays specific to the CB2 receptor showing agonist activity (EC₅₀=38.67±6.70 nM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PM226 (0.1, 1 and 10 mg/kg; administered i.p.) administration decreases the volume of the striatal lesion caused by Malonate^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

357.49

C₂₂H₃₁NO₃

1949726-13-9

CC1(C)OC2=CC(C(C)(C)CCCCCC)=CC(OC)=C2C3=C1C=NO3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gemma Navarro, et al. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front Neurosci. 2016 Sep 13;10:406.  [Content Brief]

  [2]. M Gómez-Cañas, et al. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-215.  [Content Brief]